@article{Anwar_Asif_Ahmed_Khadim_Mansur_Ahmed_2018, title={ANALYSIS OF ESTROGEN RECEPTOR (ER) AND PROGESTRONE RECEPTOR (PR) EXPRESSION IN SURFACE EPITHELIAL TUMORS OF OVARY AND ITS CORRELATION WITH THEIR CLINICAL STAGE: ER and PR Expression in Tumors of Ovary}, volume={68}, url={https://pafmj.org/PAFMJ/article/view/2276}, abstractNote={<p><strong>Objective</strong>: To evaluate ER and PR expression in epithelial ovarian cancers (EOC) and to determine its association<br>with clinical stage.<br><strong>Study Design</strong>: Cross sectional study.<br><strong>Place and Duration of Study</strong>: Histopathology department, Armed Forces Institute of Pathology (AFIP)<br>Rawalpindi, from Mar to Oct 2017.<br><strong>Material and Methods</strong>: A total of thirty three (n=33) histologically confirmed EOCs were analyzed. ER and PR<br>expression status was assessed by immunohistochemistry using Allred scoring system and was compared with<br>the clinical stage defined by The International Federation of Gynecology and Obstetrics (FIGO) staging system.<br><strong>Results</strong>: A total of thirty three (n=33) females were enrolled. Mean age of the study females was 50.8 ± 12.9 years.<br>Most frequent histologic type was serous carcinoma (SC) 60.6% (n=20) followed by mucinous carcinoma (MC)<br>15.2% (n=5), endometrioid carcinoma (EC) 9.1% (n=3), clear cell carcinoma (CC) 9.1% (n=3), Brenner tumor (MBT)<br>3% (n=1) and seromucinous carcinoma (SMC) 3% (n=1). Most patients were in clinical stage I 61% (n=20)<br>followed by stage II 24%, (n=8) and stage III 15% (n=5). Among SC, 90.0% (n=18/20) were ER and 65% (n=13/20)<br>were PR-positive. All MC and CC were ER/PR negative. Two of the three ECs were ER and one was PR-positive.<br>Higher percentage of stage I tumors exhibited ER 65% (n=13/20) and PR 45% (n=9/20) positive status (p>0.5).<br>The correlation was very weak positive between clinical stages and both ER and PR scores (Allred) r=0.11 and<br>0.15 respectively p>0.05.<br><strong>Conclusion</strong>: Higher percentages of stage I tumors exhibited ER and PR positive status yet not statistically<br>significant from stage II/III. Estimation of ER and PR receptor status may help to select the women with ovarian<br>malignancy for hormonal therapy, which is more likely to improve the response rate.</p>}, number={5}, journal={Pakistan Armed Forces Medical Journal}, author={Anwar, Madeeha and Asif, Muhammad and Ahmed, Riaz and Khadim, Muhammad Tahir and Mansur, Hamza and Ahmed, Rabia}, year={2018}, month={Oct.}, pages={1121–25} }